- Home
- IMAB vs SPRO Comparison
IMAB vs SPRO Comparison
Compare IMAB & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- SPRO
- Stock Information
- Founded
- IMAB 2014
- SPRO 2013
- Country
- IMAB United States
- SPRO United States
- Employees
- IMAB N/A
- SPRO N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- SPRO Health Care
- Exchange
- IMAB Nasdaq
- SPRO Nasdaq
- Market Cap
- IMAB 200.9M
- SPRO 164.4M
- IPO Year
- IMAB 2020
- SPRO 2017
- Fundamental
- Price
- IMAB $2.29
- SPRO $2.90
- Analyst Decision
- IMAB Strong Buy
- SPRO Buy
- Analyst Count
- IMAB 2
- SPRO 4
- Target Price
- IMAB $6.00
- SPRO $5.00
- AVG Volume (30 Days)
- IMAB 1.0M
- SPRO 1.7M
- Earning Date
- IMAB 05-15-2025
- SPRO 08-04-2025
- Dividend Yield
- IMAB N/A
- SPRO N/A
- EPS Growth
- IMAB N/A
- SPRO N/A
- EPS
- IMAB N/A
- SPRO N/A
- Revenue
- IMAB N/A
- SPRO $44,584,000.00
- Revenue This Year
- IMAB N/A
- SPRO N/A
- Revenue Next Year
- IMAB N/A
- SPRO N/A
- P/E Ratio
- IMAB N/A
- SPRO N/A
- Revenue Growth
- IMAB N/A
- SPRO N/A
- 52 Week Low
- IMAB $0.60
- SPRO $0.51
- 52 Week High
- IMAB $3.08
- SPRO $3.09
- Technical
- Relative Strength Index (RSI)
- IMAB 53.66
- SPRO 71.31
- Support Level
- IMAB $2.00
- SPRO $2.79
- Resistance Level
- IMAB $2.95
- SPRO $3.09
- Average True Range (ATR)
- IMAB 0.35
- SPRO 0.14
- MACD
- IMAB -0.07
- SPRO -0.07
- Stochastic Oscillator
- IMAB 30.53
- SPRO 50.00
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.